A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1413
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
2016 Acquired uniparental disomy of chromosome 9p in hematologic malignancies. aUPD, MPNs
2016 Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. ALL
2016 Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. ALL, HU
2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
2016 Blood donation and risk of polycythemia vera. CIs, ORs, SIRs
2016 Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. MPN-SAF, PGIC, PSIS, QOL
10  2016 Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. CLL, ET, MPN, PMF
11  2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
12  2016 Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. CALR, ET, PMF
13  2016 Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? ET, PMF
14  2016 Construction of polycythemia vera protein interaction network and prediction of related biological functions. OMIM
15  2016 Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis. DLBCL, MPNs, NHL, R-CHOP
16  2016 Extensive Bone Marrow Necrosis and Osteolytic Lesions in a Case of Acute Myeloid Leukemia Transformed from Polycythemia Vera. AML, BMN
17  2016 Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. CI, HC, HR
18  2016 High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance. ---
19  2016 Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. CALR, EPX, ET, GP, JAK2, MF, MPNs, MPO, mRNA
20  2016 Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. CI, ET, HT, MPN
21  2016 Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. FE, IE
22  2016 Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). ET, RT-PCR
23  2016 Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity. HCV, JAK2, MPNs, SAR
24  2016 JAK-2 V617F mutation increases heparanase procoagulant activity. CML, ET, PMF, TF, TFPI
25  2016 JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. ET, HU, MPNs, PMF, qRT-PCR
26  2016 Management of polycythaemia vera: a critical review of current data. ---
27  2016 Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. BCSH
28  2016 Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. ---
29  2016 Molecular biomarkers of thrombosis in myeloproliferative neoplasms. CALR, ET, IPSET-thrombosis, MPN, PMF
30  2016 Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. ET, MF, MPN, MPNs, QOL
31  2016 Myeloproliferative neoplasms: A decade of discoveries and treatment advances. CALR, CML, ET, MPL, MPN, PMF, WHO
32  2016 Myeloproliferative neoplasms: Current molecular biology and genetics. ASXL1, CALR, CBL, DNMT3A, ET, EZH2, HMGA2, IKZF1, MPNs, Ph-MPNs, PMF, SOCS, TET2, TP53
33  2016 Myeloproliferative neoplasms: Morphology and clinical practice. BM, ET, MPNs, prePMF
34  2016 Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. ET, MI
35  2016 New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. ET, MF, MPN
36  2016 Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. ET
37  2016 Outcome Disparities in Caucasian andNon-Caucasian Patients With Myeloproliferative Neoplasms. ET, MPNs
38  2016 Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. MF
39  2016 Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. CALR, ET, JAK2, MF, MPNs, PEG-IFN, PET, PPV
40  2016 PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. AIRC, CalR, ET, PLT
41  2016 PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). AIRC, ET, MPN, ROTEM
42  2016 PO-59 - Hemorheologic disturbances as thrombosis risk factor in patients with some myeloproliferative neoplasms. ALL, BNP, CRT, VTE, WBV
43  2016 Polycythemia is associated with bone loss and reduced osteoblast activity in mice. EPO, rEPO, WT
44  2016 Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis. AS
45  2016 Recent advances in understanding myelofibrosis and essential thrombocythemia. ET, MK, MPNs, PMF
46  2016 Recurrent Stroke with Rapid Development of Intracranial Stenoses in Polycythemia Vera. ---
47  2016 Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. ET, NMSC, OR
48  2016 Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. AER, SEER, SIR, SPM
49  2016 Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. HU, MPN, SAF, TSS
50  2016 TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. ET, MPN, PMF, SNP, TERT
51  2016 The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. CML, DIDO, ET, MPN, PMF
52  2016 The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. CML, ET, MPN, PMF
53  2016 Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? AML, HU
54  2016 [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients]. ET, MPN, MPN-SAF-TSS, PMF
55  2015 A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. CALR, CML, ET, HES, MPNs, PMF
56  2015 Acute Non-Atherosclerotic ST-Segment Elevation Myocardial Infarction in an Adolescent with Concurrent Hemoglobin H-Constant Spring Disease and Polycythemia Vera. STEMI
57  2015 Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. HU
58  2015 Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. ET, IMF, MPNs
59  2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs
60  2015 Association of the ACE I/D gene polymorphisms with JAK2V617F-positive polycythemia vera and essential thrombocythemia. CG, CI, ET, OR, TG
61  2015 BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. ET, Ph- MPN, PMF
62  2015 Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. AML, ET, MF
63  2015 CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. APMF, ET, MPN-U, MPNs, PMF
64  2015 Calreticulin exon 9 mutations in myeloproliferative neoplasms. CALR, ET, JAK2, MPL, MPNs, PMF
65  2015 Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. CALR, cloud-like, ECMP, EMGM, ET, MF, MPN, PMGM, PVSG
66  2015 Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. ET, MPNs, PMF
67  2015 Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. ET, JAK2, MPNs, Ph, PMF
68  2015 Concurrent Ruptured Pseudoaneurysm of the Internal Carotid Artery and Cerebral Infarction as an Initial Manifestation of Polycythemia Vera. ICA
69  2015 Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. ET, MF
70  2015 Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? CAD, CFR, ET
71  2015 Current and future treatment options for polycythemia vera. JAK2
72  2015 Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. CML, ET, MPN, PMF, SM
73  2015 Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. ET, MPNs, PMF, SVT
74  2015 Distribution of lymphocyte subpopulations in patients with polycythemia vera. NK
75  2015 Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. 3'UTR, ET, HMGA2, MPNs, PMF
76  2015 Endovascular stent graft repair of thoracic aortic mural thrombus in a patient with polycythemia vera: a word of caution. TAMT
77  2015 Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. BM, ET
78  2015 Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. HU, IFN
79  2015 Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. ET, miRNA
80  2015 Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. BM, ET, FCI, MDS, MPN, MPN-U, PMF
81  2015 From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. ET, MF, MPNs, Ph
82  2015 Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. AML, CMML, CN-LOH, ET, MC, MDS/MPN, MF, MPN, MPN-U, SNP-A
83  2015 Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis. ET, MPNs, PMF
84  2015 Hyperbaric oxygen therapy in treating post-ischemic pain caused by polycythemia vera complications: a case report. ---
85  2015 Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. ET, JAK, MF, PMF
86  2015 Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. post-PV MF
87  2015 Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders. ET, PMI, RR
88  2015 JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. CMPNs, ET, PMF
89  2015 JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. MPN, PPMF, PTMF
90  2015 Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. ET, MF, MPNs, PMF
91  2015 Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. AML, BCS, ET, MPN, OLT, PMF
92  2015 Management of symptoms in polycythemia vera and essential thrombocythemia patients. ET, MF, MPNs
93  2015 Massive intracardiac thrombosis during coronary artery bypass grafting surgery. ---
94  2015 Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study. ECM, ET, MMPs, SP
95  2015 Mechanisms of thrombogenesis in polycythemia vera. ---
96  2015 Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. ET, MPNs, PMF
97  2015 MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. ET, miRNA, PMF
98  2015 MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. ET, MMPs, MPDs, PCR-RFLP
99  2015 Molecular genetic evaluation of myeloproliferative neoplasms. CML, ET, MPNs, PMF
100  2015 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. IFN-alpha